免疫肿瘤学市场：按治疗类型、疾病类型、分销渠道、地区划分——规模、份额、展望、机会分析，2022-2030 年

免疫肿瘤学是研究和开发利用人体免疫系统对抗癌症的疗法。 免疫系统是一个由器官、细胞和分子组成的复杂网络，可以保护身体免受引起感染的外来物质的侵害。 除了发现和消灭外来物质，免疫系统还能发现和攻击异常细胞。 免疫肿瘤学使用新的免疫疗法来增强患者的免疫系统。 这些治疗针对身体的免疫系统而不是肿瘤，从而使免疫系统能够识别和靶向癌细胞。 与化学疗法和放射疗法等传统疗法不同，免疫肿瘤学不会影响健康细胞的功能。 这些治疗让您的免疫系统拥有长期记忆，因此您可以获得持久的反应。 随着时间的推移，免疫系统会适应癌症，并对癌症产生持久的反应。 免疫肿瘤学疗法可有效治疗多种癌症类型，包括非小细胞肺癌、急性髓性白血病、淋巴瘤、多发性骨髓瘤和乳腺癌。

市场动态

预测期内，主要市场参与者的产品批准等无机策略的增加预计将推动全球免疫肿瘤药物市场。 例如，2020 年 12 月，生物技术公司 Blueprint Medicines Corporation 获得美国食品药品监督管理局批准 GAVRETO（prarcetinib）用于治疗晚期或转移性 RET 突变和 RET 融合阳性甲状腺癌患者，宣布获批。 GAVRETO 是一种每日一次的口服精准治疗药物，旨在有效和选择性地靶向驱动多种肿瘤类型的 RET 改变。

这项研究的主要特点

• 本报告对全球免疫肿瘤药物市场进行了深入分析，显示了以 2021 年为基准年的预测期（2022-2030 年）的市场规模和復合年增长率 (CAGR%)。I在这里。
• 它揭示了不同细分市场的潜在收入机会，并为该市场概述了一个有吸引力的投资建议矩阵。
• 它还提供了有关市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景、主要参与者采用的竞争战略等方面的重要见解。
• 根据公司亮点、产品组合、主要亮点、绩效和战略等参数对全球免疫肿瘤学市场的主要参与者进行了概况分析。
• 本研究涵盖的主要公司包括 AbbVie Inc.、AstraZeneca、Bristol-Myers Squibb Company、Dendreon Pharmaceuticals LLC.、F. Hoffmann-La Roche Ltd.、Merck & Co., Inc.、Novartis AG、Pfizer Inc.、Sanofi、Ferring B.V.、Enzo Biochem Inc.、Celldex Therapeutics、Atara Biotherapeutics, Inc.、Apexigen、BioNTech SE、Blueprint Medicines Corporation、Regeneron Pharmaceuticals Inc.、CytomX Therapeutics, Inc.、Agenus Inc.、Betta Pharmaceuticals Co. , Ltd.、CStone Pharmaceuticals、Amgen Inc.、MediMergent, LLC、Gilead Sciences, Inc. 和 ONKO-INNATE
• 这份报告中的见解将使企业营销人员和高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。我猜。
• 《全球免疫肿瘤学市场》报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
• 利益相关者将能够通过用于分析全球免疫肿瘤学市场的各种战略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写说明

第2章市场展望

• 报告内容
  • 市场定义和范围
• 执行摘要
  • 市场概况：按治疗类型分类
  • 按疾病类型划分的市场概况
  • 市场概况：按销售渠道
  • 市场概况：按地区
• 连贯机会图 (COM)

第3章市场动态、规律及趋势分析

• 市场动态
  • 司机
  • 约束因素
  • 市场机会
• 影响分析
• 市场趋势
• 管道分析
• 收购和合作场景
• 监管场景
• 主要发展状况
• COVID-19 影响分析

第 4 章免疫肿瘤药物的全球市场 - 冠状病毒 (COVID-19) 大流行的影响

• 总体影响
• 政府举措
• COVID-19 对市场的影响

第 5 章全球免疫肿瘤学市场，按治疗类型，2017-2030

• 免疫检查点抑製剂
• PD-1
• PD-L1
• CTLA-4
• 免疫系统调节剂
• 癌症疫苗
• 肿瘤治疗病毒
• 其他

第 6 章全球免疫肿瘤药物市场，按疾病类型，2017-2030

• 黑色素瘤
• 肺癌
• 血癌
• 肾细胞癌
• 前列腺癌
• 膀胱癌
• 其他（乳腺癌、甲状腺癌等）

第 7 章全球免疫肿瘤市场，按分销渠道，2017-2030

• 医院药房
• 零售药房
• 在线药店

第 8 章全球免疫肿瘤学市场，按地区划分，2017-2030

• 北美
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地区
• 欧洲
• 英国
• 德国
• 意大利
• 法国
• 西班牙
• 俄罗斯
• 其他欧洲
• 亚太地区
• 中国
• 印度
• 日本
• 东盟
• 澳大利亚
• 韩国
• 其他亚太地区
• 中东
• 海湾合作委员会
• 以色列
• 其他中东地区
• 非洲
• 北非
• 中非
• 南非

第9章竞争格局

• AbbVie Inc.
• AstraZeneca
• Bristol-Myers Squibb Company
• Dendreon Pharmaceuticals LLC.
• Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Ferring B.V.
• Enzo Biochem Inc.
• Celldex Therapeutics
• Atara Biotherapeutics, Inc.
• Apexigen
• BioNTech SE
• Blueprint Medicines Corporation
• Regeneron Pharmaceuticals Inc.
• CytomX Therapeutics, Inc.
• Agenus Inc.
• Betta Pharmaceuticals Co., Ltd.
• CStone Pharmaceuticals
• Amgen Inc.
• MediMergent, LLC
• Gilead Sciences, Inc.
• ONKO-INNATE

第10章 章节

• 调查手法
• 关于出版社

Immuno-oncology is the study and development of treatments that take advantage of the body's immune system to fight cancer. As immune system is a complex network of organs, cells and molecules that protect the body from foreign substances that cause infection. In addition to finding and destroying foreign substances, the immune system can also locate and attack abnormal cells. Immuno-oncology uses novel immunotherapies that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immuno-oncology does not affect the functioning of healthy cells as opposed to conventional therapies such as chemotherapy and radiation therapy. Long term response can be generated with the help of these therapies as they provide long-lasting memory to the immune system. Immune system adapts to the cancer over time and provides long term response to the cancer. Immuno-Oncology therapy work against a wide variety of cancer, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others.

Market Dynamics

Increasing number of inorganic strategies such as product approval by the key market players is expected to drive the global immuno-oncology drugs market over the forecast period. For instance, in December 2020, Blueprint Medicines Corporation, a biotech company, announced that they had received an approval from the U.S. Food and Drugs Administration for GAVRETO (pralsetinib) for the treatment of patients with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancer. GAVRETO is a once-daily oral precision therapy designed to potently and selectively target RET alterations that drive multiple tumor types.

Key features of the study:

• This report provides an in-depth analysis of the global immuno-oncology drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global immuno-oncology drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Ferring B.V., Enzo Biochem Inc., Celldex Therapeutics, Atara Biotherapeutics, Inc., Apexigen, BioNTech SE, Blueprint Medicines Corporation, Regeneron Pharmaceuticals Inc., CytomX Therapeutics, Inc., Agenus Inc., Betta Pharmaceuticals Co., Ltd., CStone Pharmaceuticals, Amgen Inc., MediMergent, LLC, Gilead Sciences, Inc., and ONKO-INNATE
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immuno-oncology drugs market

Detailed Segmentation:

• Global Immuno-oncology Drugs Market, By Treatment Type:
  • Immune Checkpoint Inhibitors
    • PD-1
    • PD-L1
    • CTLA-4
  • Immune System Modulators
  • Cancer Vaccines
  • Oncolytic Virus
  • Others
• Global Immuno-oncology Drugs Market, By Disease Type:
  • Melanoma
  • Lung Cancer
  • Blood Cancer
  • Renal Cell Carcinoma
  • Prostate Cancer
  • Bladder Cancer
  • Others (Breast Cancer, Thyroid Cancer, etc.)
• Global Immuno-oncology Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Immuno-oncology Drugs Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • AbbVie Inc.*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Dendreon Pharmaceuticals LLC.
  • Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Ferring B.V.
  • Enzo Biochem Inc.
  • Celldex Therapeutics
  • Atara Biotherapeutics, Inc.
  • Apexigen
  • BioNTech SE
  • Blueprint Medicines Corporation
  • Regeneron Pharmaceuticals Inc.
  • CytomX Therapeutics, Inc.
  • Agenus Inc.
  • Betta Pharmaceuticals Co., Ltd.
  • CStone Pharmaceuticals
  • Amgen Inc.
  • MediMergent, LLC,
  • Gilead Sciences, Inc.
  • ONKO-INNATE

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Treatment Type
  • Market Snapshot, By Disease Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Pipeline Analysis
• Acquisitions and Partnerships Scenario
• Regulatory Scenario
• Key Developments
• COVID-19 Impact Analysis

4. Global Immuno-oncology Drugs Market - Impact of Coronavirus (Covid-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Immuno-oncology Drugs Market, By Treatment Type, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Immune Checkpoint Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• PD-1
• PD-L1
• CTLA-4
• Immune System Modulators
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Cancer Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Oncolytic Virus
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Immuno-oncology Drugs Market, By Disease Type, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Melanoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Lung Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Blood Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Renal Cell Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Prostate Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Bladder Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others (Breast Cancer, Thyroid Cancer, etc.)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Immuno-oncology Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Immuno-oncology Drugs Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2017 - Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• AbbVie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• AstraZeneca
• Bristol-Myers Squibb Company
• Dendreon Pharmaceuticals LLC.
• Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Ferring B.V.
• Enzo Biochem Inc.
• Celldex Therapeutics
• Atara Biotherapeutics, Inc.
• Apexigen
• BioNTech SE
• Blueprint Medicines Corporation
• Regeneron Pharmaceuticals Inc.
• CytomX Therapeutics, Inc.
• Agenus Inc.
• Betta Pharmaceuticals Co., Ltd.
• CStone Pharmaceuticals
• Amgen Inc.
• MediMergent, LLC
• Gilead Sciences, Inc.
• ONKO-INNATE

10. Section

• Research Methodology
• About Us